Search
forLearn
5 / 801 resultslearn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Research
5 / 144 results
research 1339 Casein kinase 1 inhibition in keratinocytes enhances the migration of melanocyte precursors in the hair follicle via KitL/c-Kit signaling pathway
Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.
research Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
research Wnt is back in drugmakers' sights, but is it druggable?
Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.
research PKC downregulation upon rapamycin treatment attenuates mitochondrial disease
Rapamycin treatment helps with mitochondrial disease by reducing PKC levels.
research Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
Community Join
5 / 1000+ resultscommunity Pyrilutamide update number 2 - 2 week use
An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.
community Novel Formulation To Put An End To Hair Loss Once And For All.
A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.
community Kintor money grab, unacceptable
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Kintors 1% Pyrilutamide comes in October/November
Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.